Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409571 | 0.89 | TSHR (0.70) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL6532498 | 0.87 | PARP10 (0.82) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL12569718 | 0.87 | TSHR (0.68) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL314589 | 0.86 | TSHR (0.75) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL4172039 | 0.86 | TSHR (0.67) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL3339277 | 0.86 | TSHR (0.67) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL4598393 | 0.85 | TSHR (0.66) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL315088 | 0.84 | TSHR (0.72) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL22720413 | 0.84 | TSHR (0.65) | GAAKDM4ETSHRGLAKMT2A | |
| SCHEMBL12911161 | 0.84 | TSHR (0.69) | GAAKDM4ETSHRGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| EP-0892795-B1 | PIPERIDINYLPYRAMIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2003-01-08 | — | — | EP | disclosed |
| EP-0881215-B1 | PROCESS FOR THE PREPARATION OF 4-METHYLENEPIPERIDINES | KAKEN PHARMA CO LTD (JP) | 2001-09-05 | — | — | EP | disclosed |
| CN-1110685-A | Nitrogen-containing spiro ring | MERCK & CO INC (US) | 1995-10-25 | — | — | CN | disclosed |
| WO-1995022548-A1 | TRICYCLIC SPIROPIPERIDINES | MERCK & CO., INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5439914-A | Antiarrhythmic agents; treating impaired cardiac pump funcations | MERCK & CO., INC. (US) | 1995-08-08 | — | — | US | disclosed |
| US-5298503-A | Cardiovascular | ADIR ET COMPAGNIE (FR) | 1994-03-29 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5169855-A | PIPERIDINE ETHER DERIVATIVES AS PSYCHOTROPIC DRUGS OR PLANT FUNGICIDES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| US-5114949-A | Treating disorders associated with 5HT uptake | RHONE-POULENC SANTE (FR) | 1992-05-19 | — | — | US | disclosed |
| EP-0449187-A2 | Piperidin ether derivatives as psychotropic drugs or plant fungicides | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| CN-1053613-A | Nitrogen-containing spiro ring | MERCK & CO INC (US) | 1991-08-07 | — | — | CN | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | GAA 191/4885KDM4E 3409/4885TSHR 4838/4885 |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | GAA 85/4885KDM4E 1863/4885TSHR 4255/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | GAA 191/4885KDM4E 3409/4885TSHR 4838/4885 |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | GAA 2434/4885KDM4E 3172/4885TSHR 178/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | GAA 85/4885KDM4E 1863/4885TSHR 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.